Rifampicin Drug Interactions with Pravastatin and Fluvastatin
Rifampicin can be safely coadministered with both pravastatin and fluvastatin without significant risk of drug interactions or need for dose adjustments.
Metabolic Pathways and Interaction Mechanism
The key to understanding these interactions lies in the metabolic pathways of each statin:
- Pravastatin: Undergoes non-CYP metabolism and is not dependent on cytochrome P450 enzymes 1
- Fluvastatin: Metabolized primarily by CYP2C9, not CYP3A4 1
- Rifampicin: A potent inducer of CYP3A4 (and to lesser extent other CYP enzymes)
Since rifampicin primarily induces CYP3A4, it poses significant interaction risks with statins metabolized through this pathway (simvastatin, lovastatin, atorvastatin). However, both pravastatin and fluvastatin avoid this interaction pathway entirely.
Clinical Implications
For Pravastatin:
- No dose adjustment needed when coadministered with rifampicin
- Pravastatin's non-CYP metabolism makes it immune to CYP3A4 induction effects
- Only 20% renal excretion with minimal drug-drug interaction potential 1
For Fluvastatin:
- No dose adjustment needed when coadministered with rifampicin
- CYP2C9 metabolism pathway is not significantly affected by rifampicin's CYP3A4 induction
- Only 5% renal excretion with short half-life of 3 hours 1
Important Caveats
While the FDA drug label for pravastatin 2 lists multiple interacting drugs (gemfibrozil, cyclosporine, macrolide antibiotics, niacin, fibrates, colchicine), rifampicin is notably absent from this list, supporting the lack of clinically significant interaction.
The primary concern with rifampicin would be with CYP3A4-metabolized statins (simvastatin, lovastatin, atorvastatin), where rifampicin induction could reduce statin efficacy rather than increase toxicity risk.
Practical Recommendation
Continue standard dosing of pravastatin or fluvastatin when rifampicin is initiated or discontinued. These statins represent preferred choices in patients requiring rifampicin therapy for tuberculosis or other infections, as they avoid the complex dose adjustments and monitoring required with CYP3A4-metabolized statins.